Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Surveys of Music Collections by Film Stars - 2Surprising links between autism, Alzheimer’s could change how we treat both
- 3German Winemakers Rewrite The Rules Of Riesling In A Warming World
- 4Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- 5'The Drama' plot twist, explained: What did Zendaya's character do, and what happens to her wedding?
- Nutrient Rich Natural products: Lift Your Wellbeing
- Find the Wonders of the Silk Street: Following the Antiquated Shipping lanes
- Must-See Attractions in France
- Sunken warship found off Danish coast after 225 years in ‘remarkable’ discovery
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- The most effective method to Pick The Right Speakers
- The most effective method to Make a Dazzling Site in 5 Basic Advances
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
